April 12th 2024Article
Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Social value of statins merits actions to broaden treatment, improve adherence, study finds
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Most Cancer Drugs With Accelerated Approval Don’t Show Benefit
April 18th 2024Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
FDA Approves GSK's BLA for 5-in-1 Meningococcal Vaccine
April 17th 2024The vaccine combines the antigenic components of its two meningococcal vaccines: Bexsero and Menveo. The action date is Feb. 14, 2025.
KFF: Some Medicaid Beneficiaries are Uninsured After Being Disenrolled
April 12th 2024More than half of those survey by KFF who were disenrolled from Medicaid said they put off needed medical care because of costs.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Fasenra Approved for Children with Severe Asthma
April 11th 2024Fasenra is now approved to treat patients aged 6 and older with eosinophilic asthma, a rare form of asthma.
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Most Cancer Drugs With Accelerated Approval Don’t Show Benefit
April 18th 2024Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
FDA Approves GSK's BLA for 5-in-1 Meningococcal Vaccine
April 17th 2024The vaccine combines the antigenic components of its two meningococcal vaccines: Bexsero and Menveo. The action date is Feb. 14, 2025.
KFF: Some Medicaid Beneficiaries are Uninsured After Being Disenrolled
April 12th 2024More than half of those survey by KFF who were disenrolled from Medicaid said they put off needed medical care because of costs.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Fasenra Approved for Children with Severe Asthma
April 11th 2024Fasenra is now approved to treat patients aged 6 and older with eosinophilic asthma, a rare form of asthma.